ID23983A - Inhibitor-inhibitor aminotiazol untuk kinase-kinase tergantung siklin - Google Patents

Inhibitor-inhibitor aminotiazol untuk kinase-kinase tergantung siklin

Info

Publication number
ID23983A
ID23983A IDW20000894A ID20000894A ID23983A ID 23983 A ID23983 A ID 23983A ID W20000894 A IDW20000894 A ID W20000894A ID 20000894 A ID20000894 A ID 20000894A ID 23983 A ID23983 A ID 23983A
Authority
ID
Indonesia
Prior art keywords
cincines
aminotiazol
cyclines
inhibitors
depending
Prior art date
Application number
IDW20000894A
Other languages
English (en)
Indonesian (id)
Inventor
Kyoung S Kim
S David Kimball
Zhen-Wei Cai
David B Rawlins
Raj N Misra
Michael A Poss
Kevin R Webster
John T Hunt
Wen-Ching Han
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ID23983A publication Critical patent/ID23983A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
IDW20000894A 1997-11-12 1998-11-02 Inhibitor-inhibitor aminotiazol untuk kinase-kinase tergantung siklin ID23983A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6519597P 1997-11-12 1997-11-12

Publications (1)

Publication Number Publication Date
ID23983A true ID23983A (id) 2000-06-14

Family

ID=22060972

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20000894A ID23983A (id) 1997-11-12 1998-11-02 Inhibitor-inhibitor aminotiazol untuk kinase-kinase tergantung siklin

Country Status (32)

Country Link
US (1) US6040321A (cs)
EP (1) EP1042307B1 (cs)
JP (1) JP4344084B2 (cs)
KR (2) KR20030036862A (cs)
CN (1) CN1160343C (cs)
AR (1) AR017182A1 (cs)
AT (1) ATE374771T1 (cs)
AU (1) AU730607B2 (cs)
BR (1) BR9814124A (cs)
CA (1) CA2309551C (cs)
CO (1) CO4990957A1 (cs)
CY (1) CY1107509T1 (cs)
CZ (1) CZ297907B6 (cs)
DE (1) DE69838515T2 (cs)
DK (1) DK1042307T3 (cs)
EG (1) EG24028A (cs)
ES (1) ES2296347T3 (cs)
HU (1) HUP0004559A3 (cs)
ID (1) ID23983A (cs)
IL (1) IL135589A (cs)
MY (1) MY120779A (cs)
NO (1) NO316773B1 (cs)
NZ (1) NZ503828A (cs)
PE (1) PE131699A1 (cs)
PL (1) PL204642B1 (cs)
PT (1) PT1042307E (cs)
RU (1) RU2211839C2 (cs)
TR (1) TR200001344T2 (cs)
TW (1) TW593292B (cs)
UY (1) UY25239A1 (cs)
WO (1) WO1999024416A1 (cs)
ZA (1) ZA9810332B (cs)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6214852B1 (en) * 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
US6337338B1 (en) * 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
ID30250A (id) * 1998-12-22 2001-11-15 Warner Lambert Co Kemoterapi kombinasi
US20040171632A1 (en) * 1998-12-22 2004-09-02 Gowan Richard Carleton Combination chemotherapy
CN1148349C (zh) * 1999-04-07 2004-05-05 参天制药株式会社 N-取代-N′-取代脲衍生物及其用作TNF-α生成抑制剂的用途
TR200102969T2 (tr) 1999-04-15 2002-08-21 Bristol-Myers Squibb Company Siklik protein tirozin kinaz önleyicileri.
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
CA2380389A1 (en) * 1999-07-26 2001-02-01 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
MY125768A (en) * 1999-12-15 2006-08-30 Bristol Myers Squibb Co N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
WO2001056567A1 (en) * 2000-02-04 2001-08-09 Novo Nordisk A/S 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
IT1317826B1 (it) * 2000-02-11 2003-07-15 Dompe Spa Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8.
CA2398446A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
US6534531B2 (en) * 2000-04-27 2003-03-18 Bristol-Myers Squibb Company Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
AU2001264376A1 (en) * 2000-06-15 2001-12-24 Chaconne Nsi Co., Ltd. Urea derivative useful as an anti-cancer agent and process for preparing same
PL365170A1 (en) * 2000-07-26 2004-12-27 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases
BR0113139A (pt) * 2000-08-09 2003-06-24 Agouron Pharma Compostos, seus sais, formas multiméricas, pró-drogas ou metabólitos, composições farmacêuticas, método de tratamento de uma doença ou disfunção mediana através da inibição de cdk4 ou um complexo de cdk4/ciclina, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase e método de modulação ou inibição da atividade de um receptor de proteìna cinase
US20020173507A1 (en) * 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
PT1347971E (pt) * 2000-12-21 2006-06-30 Bristol Myers Squibb Co Inibidores tiazolilicos de tirosina-cinases da familia tec
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
EP1938821B1 (en) 2001-01-25 2016-03-30 Bristol-Myers Squibb Company Dosage forms of an epothilone analogue for the treatment of cancer
DK1372650T3 (da) * 2001-03-19 2009-03-16 Novartis Ag Kombinationer indeholdende et antidiarrémiddel og en epothilon eller et epothilonderivat
ATE315555T1 (de) 2001-05-11 2006-02-15 Pfizer Prod Inc Thiazolderivate und ihre verwendung als cdk- inhibitoren
DE60212836T2 (de) * 2001-05-16 2007-01-25 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
DE60234028D1 (de) 2001-05-25 2009-11-26 Bristol Myers Squibb Co Hydantion-derivate als hemmer von matrix-metalloproteinasen
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
EP1406899B1 (en) * 2001-07-19 2006-11-15 Pfizer Italia S.r.l. Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
JP2005504065A (ja) * 2001-08-31 2005-02-10 ブリストル−マイヤーズ　スクイブ　カンパニー 癌治療のための組成物および方法
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
US7067661B2 (en) * 2002-09-04 2006-06-27 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) * 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP2006501260A (ja) * 2002-09-04 2006-01-12 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
EP1545533A1 (en) * 2002-09-04 2005-06-29 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP4700344B2 (ja) * 2002-09-04 2011-06-15 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1549638B1 (en) 2002-10-03 2007-10-03 F. Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
US7812167B2 (en) * 2002-10-03 2010-10-12 Novartis, Ag Substituted (thiazol-2-yl)-amides or sulfonamides as glucokinase activators useful in the treatment of type 2 diabetes
CA2503445C (en) * 2002-10-24 2012-07-31 Merck Patent Gesellschaft Mit Beschraenkter Haftung Methylene urea derivatives as raf-kinase inhibitors
WO2004045518A2 (en) * 2002-11-15 2004-06-03 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
EP1656542A4 (en) * 2003-07-29 2008-09-03 Bristol Myers Squibb Co BIOMARKER OF MODULATION CYCLIN-DEPENDENT KINASE
US6949895B2 (en) * 2003-09-03 2005-09-27 Axcelis Technologies, Inc. Unipolar electrostatic quadrupole lens and switching methods for charged beam transport
US7256208B2 (en) * 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
PT1723128E (pt) 2004-01-06 2013-02-27 Novo Nordisk As Heteroaril-ureias e o seu uso como activadores da glicoquinase
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
ES2631362T3 (es) * 2004-01-30 2017-08-30 Vertex Pharmaceuticals Incorporated Moduladores de transportadores de casete de unión a ATP
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
EP1568368A1 (en) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7388027B2 (en) * 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7696241B2 (en) * 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
JP2008520696A (ja) 2004-11-18 2008-06-19 ブリストル−マイヤーズ スクイブ カンパニー イキサベピロンを含む腸溶性被覆ビーズおよびその製造
EP1845094A4 (en) * 2005-01-04 2009-12-16 Univ Kanazawa Nat Univ Corp METHOD OF TUMOR SUPPRESSION AND EVALUATION OF ANTICANCER AGENT BASED ON THE INHIBITORY EFFECT OF GSK3 BETA
US20100105745A1 (en) * 2005-01-04 2010-04-29 Toshinari Minamoto Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta
WO2007006761A1 (en) 2005-07-08 2007-01-18 Novo Nordisk A/S Dicycloalkylcarbamoyl ureas as glucokinase activators
WO2007006814A1 (en) * 2005-07-14 2007-01-18 Novo Nordisk A/S Urea glucokinase activators
CN101365700A (zh) * 2005-11-15 2009-02-11 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氮杂吲唑
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7888504B2 (en) * 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
WO2008049856A2 (en) * 2006-10-25 2008-05-02 Ingenium Pharmaceuticals Gmbh Methods of treating pain using cdk inhibitors
CA2671492A1 (en) 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and cpg rich dna
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
RU2012154447A (ru) 2010-05-12 2014-06-20 Вандербилт Юниверсити Гетероциклические сульфоновые аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций
EP2580320B1 (en) 2010-06-14 2018-08-01 The Scripps Research Institute Reprogramming of cells to a new fate
AU2011323682B2 (en) * 2010-11-01 2016-06-23 Romark Laboratories L.C. Alkylsulfinyl-substituted thiazolide compounds
EP2665493B1 (en) 2011-01-20 2018-03-21 Board Of Regents, The University Of Texas System Mri markers, delivery and extraction systems, and methods of manufacture and use thereof
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2924044B1 (en) 2012-11-17 2018-10-31 Beijing Shuobai Pharmaceutical Co., LTD Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
JP6579623B2 (ja) * 2013-03-15 2019-09-25 ザ・スクリップス・リサーチ・インスティテュート 軟骨形成を誘導するための化合物及び方法
PH12016500582B1 (en) 2013-10-04 2023-06-30 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JP6980649B2 (ja) 2015-09-14 2021-12-15 インフィニティー ファーマシューティカルズ， インコーポレイテッド イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
MX375099B (es) * 2016-04-06 2025-03-06 Innovative Molecules Gmbh Derivados de aminotiazol útiles como agentes antivíricos.
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3040155C (en) 2016-10-11 2024-01-16 Euro-Celtique S.A. Compound for use in the treatment of hodgkin lymphoma
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
LT3692039T (lt) 2017-10-05 2023-03-27 Innovative Molecules Gmbh Tiazolų enantiomerai kaip antivirusiniai junginiai
WO2019241089A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
AU2019295632B2 (en) 2018-06-25 2025-03-06 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
US20220016085A1 (en) 2018-12-18 2022-01-20 Purdue Pharma L.P. Compounds for treating multiple myeloma
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
US20240132485A1 (en) * 2020-10-16 2024-04-25 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1088049A (en) * 1975-06-03 1980-10-21 Takashi Masugi 3-substituted-7-substituted alkanamido-3-cephem-4- carboxylic acid compounds and processes for preparation thereof
NO831160L (no) * 1982-04-08 1983-10-10 Erba Farmitalia Fremstilling av substituerte penem-derivater
JPS6339868A (ja) * 1986-08-04 1988-02-20 Otsuka Pharmaceut Factory Inc ジ低級アルキルフエノ−ル誘導体
DE4119756A1 (de) * 1991-06-15 1992-12-17 Basf Ag Aminoalkylsubstituierte 5-mercaptothiazole, ihre herstellung und verwendung
JPH0859669A (ja) * 1994-06-13 1996-03-05 Takeda Chem Ind Ltd セフェム化合物、その製造法及び剤
US5856347A (en) * 1994-11-29 1999-01-05 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof

Also Published As

Publication number Publication date
CA2309551C (en) 2006-03-28
KR20030036862A (ko) 2003-05-09
HUP0004559A3 (en) 2002-05-28
ES2296347T3 (es) 2008-04-16
CN1278806A (zh) 2001-01-03
TR200001344T2 (tr) 2000-09-21
PE131699A1 (es) 2000-03-08
NO20002153L (no) 2000-05-11
PT1042307E (pt) 2007-11-15
IL135589A (en) 2004-06-20
EP1042307A4 (en) 2003-01-29
DK1042307T3 (da) 2008-01-28
UY25239A1 (es) 2000-12-29
EG24028A (en) 2008-03-26
RU2211839C2 (ru) 2003-09-10
US6040321A (en) 2000-03-21
KR20010031896A (ko) 2001-04-16
CZ297907B6 (cs) 2007-04-25
AU730607B2 (en) 2001-03-08
AR017182A1 (es) 2001-08-22
JP2001522842A (ja) 2001-11-20
DE69838515T2 (de) 2008-07-03
ATE374771T1 (de) 2007-10-15
NO316773B1 (no) 2004-05-03
PL340540A1 (en) 2001-02-12
DE69838515D1 (de) 2007-11-15
BR9814124A (pt) 2000-10-03
HUP0004559A1 (hu) 2002-04-29
AU1295599A (en) 1999-05-31
TW593292B (en) 2004-06-21
CN1160343C (zh) 2004-08-04
PL204642B1 (pl) 2010-01-29
CZ20001744A3 (en) 2001-05-16
EP1042307B1 (en) 2007-10-03
CA2309551A1 (en) 1999-05-20
MY120779A (en) 2005-11-30
NO20002153D0 (no) 2000-04-27
JP4344084B2 (ja) 2009-10-14
CO4990957A1 (es) 2000-12-26
NZ503828A (en) 2003-03-28
IL135589A0 (en) 2001-05-20
CY1107509T1 (el) 2013-03-13
KR100454426B1 (ko) 2004-10-26
ZA9810332B (en) 2000-05-11
WO1999024416A1 (en) 1999-05-20
EP1042307A1 (en) 2000-10-11

Similar Documents

Publication Publication Date Title
ID23983A (id) Inhibitor-inhibitor aminotiazol untuk kinase-kinase tergantung siklin
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
NO20002121D0 (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
FI963597A7 (fi) Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no) Fibronectin-adhesjonsinhibitorer
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
FI972160A0 (fi) Matriisimetalloproteaasi-inhibiittorit
NO995433D0 (no) Protease-inhibitorer
DE69906554D1 (de) P38 inhibitoren
ID19198A (id) Inhibitor metaloprotease heterosiklik
PT1181017E (pt) Inibidores de metaloproteases
DK1004669T3 (da) Hidtil ukendte differentieringsinhibitor
FI973492L (fi) NO-syntaasin estäjät
DE69716615D1 (de) Heterozyklische metalloproteaseinhibitoren
NO996578D0 (no) Urokinase-inhibitorer
PT1194404E (pt) Inibidores de aspartil-protease
PT1113965E (pt) Acessorio para gargalo de garrafa
NO995435D0 (no) Protease-inhibitorer
NO995434L (no) Proteaseinhibitorer
NO995268D0 (no) Proteaseinhibitorer
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
NO980643D0 (no) Propylendopeptidase inhibitorer
ID23196A (id) Gandaran untuk lampuflouresen
NO993161D0 (no) Cyklooksygenaseinhibitor
BR9610514A (pt) Inibidores cicloantihelmínticos